Page last updated: 2024-12-07

3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine: a non-peptide angiotensin II-receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131857
CHEMBL ID71162
SCHEMBL ID685515
MeSH IDM0222785

Synonyms (20)

Synonym
4''-(2-cyclopropyl-7-methyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-carboxylic acid
bdbm50049212
e4177
CHEMBL71162 ,
e-4177
L004970
2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid
2-[4-[(8-cyclopropyl-5-methyl-2,7,9-triazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)methyl]phenyl]benzoic acid
135070-05-2
3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridine
e 4177
(1,1'-biphenyl)-2-carboxylic acid, 4'-((2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridin-3-yl)methyl)-
SCHEMBL685515
2-cyclopropyl-3-(2'-carboxybiphenyl-4-yl)methyl-7-methyl-3h-imidazo[4,5-b]pyridine
2-cyclopropyl-3-(2'-carboxybiphenyl-4-yl)methyl-7-methyl-3h-imidazo-[4,5-b]pyridine
VWWMGPCUZVOLLK-UHFFFAOYSA-N ,
DTXSID50159239
57g709; e 1477
4'-((2-cyclopropyl-7-methyl-3h-imidazo[4,5-b]pyridin-3-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid
AKOS040748296
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.05200.00040.15553.8000AID37839
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)0.05200.00040.13343.8000AID37839
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID37839Inhibitory activity against Angiotensin II receptor, type 1 in rat aortic membranes1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID568917Binding affinity to angiotensin AT1 receptor in rat adrenal cortical membranes2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID167381Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID568783Antagonist activity at angiotensin AT1 receptor in rabbit aorta2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's17 (85.00)18.2507
2000's2 (10.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.13 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]